The one and only conference covering the entire CIS pharmaceutical sector.

26 - 28 February 2020

Radisson Royal Hotel, Moscow, Russia

INITIAL SPEAKER CONFIRMATIONS

Roger Elia is the General Manager of Merck Biopharma in CIS

Born in 1976 in Lebanon. Roger holds MBA in Finance & Marketing. Roger lived and worked in Lebanon, Russia, CIS and South Korea. Since 2018 he has been living and working in Russia.

 Professional background

2018 – now
General Manager of Merck Biopharma in CIS
2015– 2018
Business Unit Head at Merck Ltd Korea
2014 – 2015
Strategic Alliance Leader at Merck LLC Russia
2011 – 2014
Marketing Manager at Merck LLC Russia
2009– 2011
Market Access and Pricing Head at Novartis Oncology Russia
2003– 2009
Various management positions at Pharmonyx Ltd in Russia and CIS
1994 – 2003
Medical Academy, Moscow

As an engagement manager (Russia & CIS), Olga is Responsible for leading and management of consulting project and business development in Russia and CIS countries

More than 10 years experience in Pharmaceutical and Chemical industries with focus on Strategy & Business development, operational and commercial excellence

Expertise in identifying and evaluation of portfolio expansion and acquisition opportunities, potential assessment, pricing and market access, new geography expansion and strategy development, marketing strategies and consumer health, supply chain and demand planning

Before joining IQVIA in 2014 worked as Strategy Development manager in Russian chemical company and Novartis Consumer Health

Graduated from Lomonosov Moscow State University with Master of Science degree in Mathematics and completed Business Academy in Stockholm School of Economics

Marina Durmanova is the President of the Republic of Kazakhstan Pharmaceutical Activity Support and Development Association the participants of which are the national and foreign pharmaceuticals manufacturers, distribution companies and pharmacy organizations. Represented by Marina Durmanova, the Association takes an active part in standard setting process. She is a member of the task groups under the Mazhilis (the lower house) of the Parliament that discuss various draft laws in the public health sphere.

The Association s a member of the Social Council under the Republic of Kazakhstan Public Health Ministry, National Scientific Council operating in the sphere of the life science and health with pharmaceutical science as the priority line, Republic of Kazakhstan Public Health Ministry’s collegium, formulary commission under the RK Public Health Ministry, Expert and Business Council under the Almaty Akimat (City Executive Board). She has been accredited by the Republic of Kazakhstan National Chamber of Entrepreneurs and is a member of the Pharmaceutical and Medical Industry Committee under the RK NCE Atameken.

The Republic of Kazakhstan Pharmaceutical Activity Support and Development Association is a member of the task group in charge of development of general approach to control of pharmaceuticals and medical products circulation within the boundaries of the Customs Union and the Common Economic Area.

Marina Durmanova has repeatedly received state awards for her contribution to development of the national public health sphere.   

Sergei Groshev

Medical doctor and marketer, graduated from the Plekhanov Russian University of Economics (Moscow), PhD.

In the pharmaceutical industry since 2007. In Nycomed (later – Takeda) he has grown from the 1st Medical representative for the Kyrgyzstan southern region to the Representative Office in Uzbekistan Head, created the Asia-Caucasus Cluster Medical department, successfully developed the cardiology portfolio by 3 products launch to the Kazakhstani market.

In Chimpharm JSC (Santo, Polpharma group) cardiology division has raised on the relevant market from the 4th position to the 2nd when he managed the Rx Marketing department. He also participated in the corporate project group for launches strategies and mechanics.

In the Acino Kaz LLP he is in charge of oncology and paediatric endocrinology.

Sergei Groshev has been administrating the Facebook page for head and neck cancer early signs, was awarded with the Saint-Petersburg Government Committee for Youth Politic and Collaboration with Public Organizations, has been passed to the semi-final of Leaders of Russia-2020 (the Public Health course).

Dr. Aleksandr Solodovnikov has 14 years of clinical trial expertise as an  investigator, CRA, clinical operations trial lead and clinical operations manager in fields of Endocrinology, Psychiatry, Cardiology, Pulmonology, Oncology, Hematology, Dermatology, Neurology, Surgery and Infectious Diseases (more than 30 trials, phase I-IV).

Aleksandr graduated from the Ural State Medical Academy (now University) in 2003 and started his scientific career at the Chair of preventative and family medicine resulting in a PhD in Rheumatology in 2009. Dr. Solodovnikov is now an associate professor of this Chair supervising edivence-based medicine and biostatistics fields.  Aleksandr received his training in statistics and epidemiology at the University of Manchester, UK, and at the Erasmus University, the Netherlands, and personally prepared and conducted more than 300 various statistical analyses in various statistical software packages (NCSS, Stata, R, SPSS, Statistica and other) and provided a lot of consultations in this field. He further developed his professional skills in clinical research by taking the “Principles and Practice of Clinical Research” course at Harvard Medical School in 2014. In 2016, Aleksandr also successfully completed the “Project Management Professional”.

Dr. Solodovnikov is a skillful trainer and lecturer, and has conducted numerous GCP trainings as well as seminars in biostatistics, evidence-based medicine, clinical research, drug development and regulations in clinical trials. He knows local, regional (EAEU) and international clinical trial regulations and guidelines well, and took part in the development of hundreds of clinical trial documents for medicines, medical devices, cosmetic and dietary products, and biologically active substances, starting from study concept and ending with the final protocol.